Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.
Sutapa Barua,Samir Mitragotri +1 more
Reads0
Chats0
TLDR
This review focuses on the current understanding of penetration of NPs through biological barriers, andphasis is placed on transport barriers and not immunological barriers.About:
This article is published in Nano Today.The article was published on 2014-04-01 and is currently open access. It has received 788 citations till now.read more
Citations
More filters
Journal ArticleDOI
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm,Anthony J. Tavares,Qin Dai,Seiichi Ohta,Seiichi Ohta,Julie Audet,Harold F. Dvorak,Warren C. W. Chan +7 more
TL;DR: This Perspective explores and explains the fundamental dogma of nanoparticle delivery to tumours and answers two central questions: ‘ how many nanoparticles accumulate in a tumour?’ and ‘how does this number affect the clinical translation of nanomedicines?'
Journal ArticleDOI
Nanoparticles in the clinic.
TL;DR: This work highlights the diversity of nanoparticle types, the key advantages these systems have over their free drug counterparts, and their overall potential in influencing clinical care, and focuses on current clinical trials for nanoparticle formulations that have yet to be clinically approved.
Journal ArticleDOI
Rethinking cancer nanotheranostics.
TL;DR: The evolution and state of the art of cancer nanotheranostics is described, with an emphasis on clinical impact and translation, and how diagnosis and therapy are interwoven to solve clinical issues and improve treatment outcomes.
Journal ArticleDOI
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization.
TL;DR: The typical cancer‐drug‐delivery process of an intravenously administered nanomedicine is analyzed and it is concluded that the delivery involves a five‐step CAPIR cascade and that high efficiency at every step is critical to guarantee high overall therapeutic efficiency.
Journal ArticleDOI
Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment
TL;DR: This review article summarized the recent progress in various nanoformulations for cancer therapy, with a special emphasis on tumour microenvironment stimuli-responsive ones, which it believes offer a good chance for the practical translation of nanoparticle formulas into clinic.
References
More filters
Journal ArticleDOI
Targeting HIF-1 for cancer therapy
TL;DR: Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biology, including angiogenesis, cell survival, glucose metabolism and invasion.
Journal ArticleDOI
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
TL;DR: In addition to their role in extracellular matrix turnover and cancer cell migration, MMPs regulate signaling pathways that control cell growth, inflammation, or angiogenesis and may even work in a nonproteolytic manner.
Journal ArticleDOI
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Kandice R. Levental,Hongmei Yu,Laura Kass,Johnathon N. Lakins,Mikala Egeblad,Janine T. Erler,Sheri F. T. Fong,Katalin Csiszar,Amato J. Giaccia,Wolfgang Weninger,Mitsuo Yamauchi,David L. Gasser,Valerie M. Weaver +12 more
TL;DR: Reduction of lysyl oxidase-mediated collagen crosslinking prevented MMTV-Neu-induced fibrosis, decreased focal adhesions and PI3K activity, impeded malignancy, and lowered tumor incidence, and data show how collagenCrosslinking can modulate tissue fibrosis and stiffness to force focal adhesion, growth factor signaling and breast malignancies.
Journal ArticleDOI
Integrins in cancer: biological implications and therapeutic opportunities
TL;DR: Clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.
Journal ArticleDOI
Delivering nanomedicine to solid tumors
TL;DR: In this paper, the authors review the barriers to the delivery of cancer therapeutics and summarize strategies that have been developed to overcome these barriers and discuss design considerations for optimizing the nanoparticles to tumors.